Time spent with oxygen levels within a safe range using the a new oxygen delivery device in automatic or manual mode in adults admitted to hospital (with or without COVID-19)
- Conditions
- Coronavirus infectious disease 2019 (COVID-19)Respiratory failureInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12622000433707
- Lead Sponsor
- Fisher and Paykel Healthcare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 62
• Supplemental oxygen requirement >= 2L/min nasal prongs for those with a target SpO2 of 92-96% appropriate (not at risk of hypercapnic respiratory failure)
• Supplemental oxygen requirement >= 1L/min nasal prongs for those with a target SpO2 of 88-92% appropriate (risk of hypercapnic respiratory failure)
• Requirement for NHF/CPAP/ Bi-level therapy as deemed appropriate by the patient’s treating clinician
• Expected duration of oxygen therapy >9 hours
• Measured for at least 8 hours of the initial 9 hour study period
• Age < 18
• Imminent (within 1 hour) need for invasive mechanical ventilation or intensive care unit support (based on treating clinician assessment)
• Haemodynamic instability (systolic blood pressure <90mmHg or requirement for vasopressor or inotropic support)
• Patient receiving end of life care
• Risk of barotrauma, as assessed by the investigator
• Nasal or facial conditions precluding use of NHF, CPAP or Bi-level
• Pregnancy or breastfeeding
• Cognitive impairment or impaired consciousness precluding informed consent
• Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method